Alexander Schwarz, 622319 E Fairmount Ave, Baltimore, MD 21224

6610630, Aug 26, 2003

Feb 13, 1998

09/023266

Alexander Schwarz - Brookline MA
Meir Wilchek - Rehovot, IL

Ciphergen Biosystems, Inc. - Fremont CA

B01J 2022

502401, 502402, 502403, 502400, 530412, 530413, 530415, 530420

A pseudobioaffinity chromatography adsorbent adapted for use in selectively adsorbing immunoglobulins. In one embodiment, the adsorbent includes: (a) a solid support material; and (b) a ligand immobilized on the surface of the solid support material, said ligand being a compound of the formula wherein Y is selected from the group consisting of S, SCH , O, NH, NCH , CH and CR R wherein at least one of R and R is not hydrogen; wherein each of Y , Y and Y is selected from the group consisting of N, NCH , CH, and CR wherein R is not hydrogen; and wherein at least two of Y , Y , Y and Y are neither CH , CH, CR nor CR R.

6713646, Mar 30, 2004

Jun 27, 2002

10/186251

Hongmin Zhang - Duxbury MA
Alexander Schwarz - Brookline MA

Biosphere Medical - Rockland MA

C07C 6952

560205, 560312

One aspect of the present invention relates to base-labile crosslinkers. A second aspect of the present invention relates to degradable crosslinked polymers and hydrogels comprising a base-labile crosslinker. The present invention also relates to a method of influencing the degradation rate of a crosslinked polymer or hydrogel, comprising the step of incorporating uncharged acrylamides into the crosslinked polymer or hydrogel.

6884905, Apr 26, 2005

Feb 25, 2003

10/374508

Hongmin Zhang - Duxbury MA, US
Alexander Schwarz - Brookline MA, US

Biosphere Medical - Rockland MA

C07C271/00

560158

One aspect of the present invention relates to base-labile, carbamate-containing crosslinkers. A second aspect of the present invention relates to degradable crosslinked polymers and hydrogels comprising a base-labile, carbamate-containing crosslinker. The present invention also relates to methods of preparing base-labile, carbamate-containing crosslinkers. Another aspect of the present invention relates to methods of preparing cross-linked polymers and hydrogels comprising a base-labile, carbamate-containing crosslinker.

7135593, Nov 14, 2006

Mar 22, 2004

10/806036

Hongmin Zhang - Duxbury MA, US
Alexander Schwarz - Brookline MA, US

Biosphere Medical, Inc. - Rockland MA

C07C 96/52
C07C 239/00
C08F 20/00

560205, 560312, 526328

One aspect of the present invention relates to base-labile crosslinkers. A second aspect of the present invention relates to degradable crosslinked polymers and hydrogels comprising a base-labile crosslinker. The present invention also relates to a method of influencing the degradation rate of a crosslinked polymer or hydrogel, comprising the step of incorporating uncharged acrylamides into the crosslinked polymer or hydrogel.

7700086, Apr 20, 2010

Nov 5, 2004

10/983164

Alexander Schwarz - Brookline MA, US

Pluromed, Inc. - Woburn MA

A61K 31/74

424 7808, 424400, 424422, 424426

One aspect of the present invention relates to a method of occluding a vascular site in a mammal, comprising the step of introducing into the vasculature of a mammal at or proximal to a surgical site, a composition comprising at least one optionally purified inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily occluding a vascular site of said mammal, wherein said temporarily occluded vasculature site is kept in a substantially cylindrical shape.

7838699, Nov 23, 2010

Mar 14, 2003

10/389708

Alexander Schwarz - Brookline MA, US
Hongmin Zhang - Duxbury MA, US

Biosphere Medical - Rockland MA

C07C 69/52
C07C 239/00
C08F 20/00
A61F 13/00

560205, 560312, 526328, 424422

One aspect of the present invention relates to a method of temporarily embolizing a blood vessel using a hydrolytically degradable crosslinked hydrogel as an embolus. In certain embodiments, the hydrolytically degradable crosslinked hydrogel substantially hydrolyzes only at about physiological pH. In certain embodiments of the method, the hydrolytically degradable crosslinked hydrogel is stable at low pH. In certain embodiments of the method, the hydrolytically degradable crosslinked hydrogel comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound. It is to be understood that both the foregoing general description and the following detailed description are exemplary, and are intended to provide further explanation of the invention as claimed.

8198365, Jun 12, 2012

May 8, 2008

12/117367

Edward P. Ingenito - North Quincy MA, US
James A. Krom - Belmont MA, US
Alexander Schwarz - Brookline MA, US
Larry W. Tsai - Boston MA, US

Aeris Therapeutics, LLC - Woburn MA

C08F 8/00

525 61, 525 56, 528425, 604 28

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e. g. , blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.

8361455, Jan 29, 2013

Apr 27, 2006

11/412407

W. Scott McDougal - Manchester MA, US
Dianne E. Sacco - Charlestown MA, US
Alexander Schwarz - Brookline MA, US
Jean-Marie Vogel - Lincoln MA, US

Pluromed, Inc. - Woburn MA
The General Hospital Corporation - Boston MA

A61K 31/77

424 7838, 424 7808, 424 7834, 424 7837, 606 25

One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.